Opiranserin (VVZ-149) is a novel non-opioid, non-steroidal intravenous analgesic with triple antagonistic activity at glycine transporter 2 (GlyT2), purine 2 receptor 3 (P2X3), and serotonin receptor (5-HT2A). Its half-maximal inhibitory concentrations are 0.86, 0.87, and 1.3 μM for GlyT2, P2X3, and 5-HT2A, in the orde...
Kyung-Hoon Kim· The Korean Journal of Pain· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.